Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2024 - 2025)

Corvus Pharmaceuticals' (CRVS) quarterly Gains from Investment Securities came in at -$2.0 million in Q2 2025, down 10.79% year-on-year from -$2.3 million in Q2 2024, and up 91.99% quarter-over-quarter from -$25.1 million in Q1 2025.

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Corvus Pharmaceuticals' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$2.0 million for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities fell 10.79% year-over-year to -$2.0 million in Q2 2025; TTM through Dec 2025 was -$27.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$27.1 million, down 181.26% from the prior year.
  • Gains from Investment Securities improved to -$2.0 million in Q2 2025 per CRVS's latest filing, from -$25.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $32.8 million in Q3 2024 and bottomed at -$25.1 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn -
2 Nanobiotix 1,908.96 Bn 1,908.90 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 474.03 Bn 469.24 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.96 Bn 50.77 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 Corvus Pharmaceuticals 1.18 Bn 942.24 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 -2.01 Mn
Jun 30, 2025 -2.01 Mn
Mar 31, 2025 -25.13 Mn
Mar 31, 2025 -25.13 Mn
Dec 31, 2024 2.37 Mn
Dec 31, 2024 2.37 Mn
Sep 30, 2024 32.85 Mn
Sep 30, 2024 32.85 Mn
Jun 30, 2024 -1.82 Mn
Jun 30, 2024 -1.82 Mn